A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1277
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2015 Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ET, MIAs
2015 Calreticulin exon 9 mutations in myeloproliferative neoplasms. CALR, ET, JAK2, MPL, MPNs, PMF
2015 Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. CALR, cloud-like, ECMP, EMGM, ET, MF, MPN, PMGM, PVSG
2015 Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. ET, MF
2015 Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: The missing piece in the puzzle of their increased cardiovascular risk? CAD, CFR, ET
2015 Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. 3'UTR, ET, HMGA2, MPNs, PMF
2015 Endovascular stent graft repair of thoracic aortic mural thrombus in a patient with polycythemia vera: a word of caution. TAMT
2015 MMP2 Gene-735 C/T and MMP9 gene -1562 C/T Polymorphisms in JAK2V617F Positive Myeloproliferative Disorders. ET, MMPs, MPDs, PCR-RFLP
2015 Novel and emerging therapies for the treatment of polycythemia vera. ---
10  2015 Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. AVWS, CALR, ET, JAK2, MPL
11  2015 Target hematologic values in the management of essential thrombocythemia and polycythemia vera. ET
12  2015 [Research progress of myeloproliferative neoplasms]. allo-ASCT, ET, MPN, PMF
13  2014 A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. ASO, B2M, ET, GUSB, PLTs, PMF
14  2014 A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. ET, mPV, WHO
15  2014 A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. JAK2
16  2014 Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect? MPN
17  2014 Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. ET, MPNs, TET2
18  2014 Angiogenic activity in the sera of patients with post-kidney transplant erythrocytosis. PTE, VEGF
19  2014 Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. ET, MF, MPNs
20  2014 Antiplatelet therapy in the management of myeloproliferative neoplasms. ASA, ECLAP, ET
21  2014 Application of the optimized CO-rebreathing method for determination of hemoglobin mass in patients with polycythemia vera. BSA, LBM, RCV
22  2014 Assessing disease burden in patients with classic MPNs. ET, MF, MPN
23  2014 Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. CHR, ET
24  2014 Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. CVT, ET, MPNs, PMF
25  2014 Chorea disclosing a polycythemia vera. JAK2
26  2014 Chronic myeloproliferative diseases. ET, PMF
27  2014 Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. ET, MPN
28  2014 Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ET
29  2014 Cluster-like headache responsive to phlebotomy. ---
30  2014 Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. ET, MGUS, MM, MPNs, PMF
31  2014 Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. EEC, PVSG
32  2014 Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. ET, IL, JAK2, MPNs
33  2014 Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme. EMR, MPN
34  2014 Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. iPSCs
35  2014 Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. DIPSS, ET, MF, MPNs
36  2014 Dkk3 levels in patients with myeloproliferative neoplasms. Dkk-3, ET, MPN, PMF
37  2014 Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. ---
38  2014 Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome. EPO, JAK2
39  2014 Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. ET, MF, MPN, PMF
40  2014 Epidemiology of myeloproliferative neoplasms in the United States. ET, MF, MPNs
41  2014 Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. BM, ET, MPN, Ph-neg, PMF, WHO
42  2014 Essential thrombocythemia: Rare cause of chorea. ET, MPD
43  2014 Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. ET, HRU, MF, MPN
44  2014 Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. GP, MPN
45  2014 How common are myeloproliferative neoplasms? A systematic review and meta-analysis. ET, MPNs, PMF
46  2014 How I treat polycythemia vera. ---
47  2014 Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. ET, HU, OHR
48  2014 Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. ET, IFN
49  2014 Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis? MF, MPNs
50  2014 It is time to change thrombosis risk assessment for PV and ET? ET
51  2014 Jak-2 positive myeloproliferative neoplasms. CEL-NOS, CML, CNL, ET, MPNs, PMF, TKIs
52  2014 JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms. CMPNs, ET, JAK2, PMF
53  2014 JAK2V617F allele burden in patients with myeloproliferative neoplasms. ARMS-PCR, ET, MF, MPNs, RQ-PCR
54  2014 JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. ET, PLA, TF
55  2014 JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. ET, UPD
56  2014 JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. ET, IRR
57  2014 JAK2V617F mutation and endogenous erythroid colony formation in patients with polycythaemia vera. Agar-LCM, AS-PCR, EEC, EPO, WHO
58  2014 JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. MPNs, RCM
59  2014 JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. ET, MPNs, PI3K, RPA
60  2014 Life, genes, and death in Ph- MPNs. ET, PMF
61  2014 Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. BT, CALR, CI, ET, HR, JAK2, MPL, PMF
62  2014 Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. ET, IFN-gamma, JAK2, STAT1
63  2014 Masked polycythemia vera (mPV): results of an international study. mPV, mPV
64  2014 Masked polycythemia vera diagnosed according to WHO and BCSH classification. BCSH, BM, Hb, Hct, mPV, WHO
65  2014 Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms. ET, MF, MPN
66  2014 Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis. ET, MF, PMF
67  2014 Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy. ATP, BCR-ABL, CALR, ET, MPL, MPN, PMF, STAT
68  2014 Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients. ECP, MAP
69  2014 Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. ET
70  2014 Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis. CLT, CR, ECP, MCF
71  2014 Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. JAK2
72  2014 Polycythemia vera syndrome--as a protrombothic state. CVD, PC, PS
73  2014 Polycythemia vera transforming to myelofibrosis and then biphenotype acute leukemia. BAL, MF, MPN
74  2014 Presence of calreticulin mutations in JAK2-negative polycythemia vera. BFU-E, CALR, JAK2, MPL
75  2014 Prognostication in MF: from CBC to cytogenetics to molecular markers. ET, MF, PMF
76  2014 Rethinking the diagnostic criteria of polycythemia vera. BCSH, BM, mPV, PVSG, WHO
77  2014 Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. ET, MPNs, RBCs
78  2014 Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). ET, MF, MPN, OS, SEER, US
79  2014 The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis. BV, DeltaHct, ER, HH, RBC, SE, TE
80  2014 The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. ET, MPNs, Ph, PMF
81  2014 The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells. HSC, MPNs, PEG-IFN alpha-2a, PMF
82  2014 The role of alpha-acidic glycoprotein in formation of bleeding abnormalities in patients with myeloproliferative neoplasms. AGP, ET, LDH, MPN, PMF
83  2014 The role of parathyroidectomy in JAK2 mutation negative polycythemia vera. ---
84  2014 The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera. AUC, CEIA, EPO, RIA
85  2014 The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. MDA, OSI, TOS
86  2014 Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. ET, HU
87  2014 Therapy for myeloproliferative neoplasms: when, which agent, and how? MF
88  2014 Therapy for myeloproliferative neoplasms: when, which agent, and how? MF
89  2014 Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia. CV, ET
90  2014 Vertebral artery thrombosis: a rare presentation of primary polycythaemia. MPN
91  2014 WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. ET, MPNs, PMF
92  2014 Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. ET, HSCs, MF, ROS
93  2014 [JAK2V617F mutation and TNF-alpha expression in myeloproliferative neoplasms and their correlation]. ET, MF, MPN
94  2014 [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment]. Ph, TKI
95  2013 A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. HC, HDACi, MPN, MTD
96  2013 Aberrant expression of signaling proteins in essential thrombocythemia. ERbeta, ET
97  2013 ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. CAT, ET, TG
98  2013 Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. MPN
99  2013 An unknown cause of aortic valve stenosis: polycythemia vera. Ht
100  2013 Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. FTY720-P, PP2A